Antibody Immunosuppressive Therapy in Solid-organ Transplant: Part I

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2010 Feb 13

PMID 20150766

Citations 25

Authors

Nadim Mahmud

Dusko Klipa

Nasimul Ahsan

Affiliations

Soon will be listed here.

Abstract

Currently, a wide variety of both polyclonal and monoclonal antibodies are being routinely utilized to prevent and treat solid organ rejection. More commonly, these agents are also administered in order to delay introduction of calcineurin inhibitors, especially in patients with already compromised renal function. While these antibody therapies dramatically reduced the incidence of acute rejection episodes and improved both short and long-term graft survival, they are also associated with an increased incidence of opportunistic infections and neoplastic complications. Therefore, effective patient management must necessarily balance these risks against the potential benefits of the therapy.

Citing Articles

Current and emerging approaches to cochlear immunosuppression with translation to human inner ear stem cell therapy: A systematic review.

Creber N, Muzaffar J, Gowrishankar S, Borsetto D, Phillips V, Smith M PLoS One. 2025; 20(2):e0318165.

PMID: 39946404 PMC: 11825040. DOI: 10.1371/journal.pone.0318165.

Structure, function, and immunomodulation of the CD8 co-receptor.

Srinivasan S, Zhu C, McShan A Front Immunol. 2024; 15:1412513.

PMID: 39253084 PMC: 11381289. DOI: 10.3389/fimmu.2024.1412513.

Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis.

Saowapa S, Polpichai N, Siladech P, Wannaphut C, Tanariyakul M, Wattanachayakul P Cureus. 2024; 16(1):e52527.

PMID: 38371002 PMC: 10874301. DOI: 10.7759/cureus.52527.

A Comprehensive Landscape of Malignancy After Double Lung Transplantation.

Lee J, Yang A, Chung L, Yu J, Lee Y, Kim H Transpl Int. 2023; 36:11552.

PMID: 37663524 PMC: 10468575. DOI: 10.3389/ti.2023.11552.

TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome.

Carrara S, Harwardt J, Grzeschik J, Hock B, Kolmar H Front Immunol. 2022; 13:1051875.

PMID: 36439165 PMC: 9687101. DOI: 10.3389/fimmu.2022.1051875.

References

Offner G, Toenshoff B, Hocker B, Krauss M, Bulla M, Cochat P . Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation. 2008; 86(9):1241-8. DOI: 10.1097/TP.0b013e318188af15. View

Calne R, Rolles K, White D, Thiru S, Evans D, McMaster P . Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979; 2(8151):1033-6. DOI: 10.1016/s0140-6736(79)92440-1. View

Abbott K, Hypolite I, Poropatich R, Hshieh P, Cruess D, Hawkes C . Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis. 2002; 3(4):203-11. DOI: 10.1034/j.1399-3062.2001.30404.x. View

Reams B, Musselwhite L, Zaas D, Steele M, Garantziotis S, Eu P . Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant. 2007; 7(12):2802-8. DOI: 10.1111/j.1600-6143.2007.02000.x. View

Brennan D, Flavin K, Lowell J, Howard T, Shenoy S, Burgess S . A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999; 67(7):1011-8. DOI: 10.1097/00007890-199904150-00013. View

Rosen H, Shackleton C, Higa L, Gralnek I, FARMER D, McDiarmid S . Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol. 1997; 92(9):1453-7. View

Chatenoud L, Bach J . [T lymphocyte activation induced by monoclonal anti-CD3 antibodies: physiopathology of cytokine release]. C R Seances Soc Biol Fil. 1991; 185(5):268-77. View

Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-75. DOI: 10.1056/NEJMoa067411. View

Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A . Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007; 7(3):560-70. DOI: 10.1111/j.1600-6143.2006.01645.x. View

10.

Meier-Kriesche H, Arndorfer J, Kaplan B . Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol. 2002; 13(3):769-772. DOI: 10.1681/ASN.V133769. View

11.

Marino I, Doria C, Scott V, Foglieni C, Lauro A, Piazza T . Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients. Transplantation. 2004; 78(6):886-91. DOI: 10.1097/01.tp.0000134970.92694.68. View

12.

Noel C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M . Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol. 2009; 20(6):1385-92. PMC: 2689909. DOI: 10.1681/ASN.2008101037. View

13.

Heifets M, Saeed M, Parikh M, Sierka D, Kumar M . Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect. Drugs Aging. 2004; 21(11):747-56. DOI: 10.2165/00002512-200421110-00005. View

14.

Issa N, Fishman J . Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009; 48(6):772-86. DOI: 10.1086/597089. View

15.

Vincenti F, Kirkman R, LIGHT S, Bumgardner G, Pescovitz M, Halloran P . Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998; 338(3):161-5. DOI: 10.1056/NEJM199801153380304. View

16.

Potter B, Giannetti N, Routy J, Cecere R, Cantarovich M . CD25 saturation rate in heart transplant patients receiving two-dose daclizumab induction. Transplantation. 2005; 79(7):857-8. DOI: 10.1097/01.tp.0000152661.43574.6c. View

17.

Hibberd P, Cosimi A, Schooley R, Isaacson D, Doran M, Delvecchio A . Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation. 1992; 53(1):68-72. DOI: 10.1097/00007890-199201000-00013. View

18.

Flechner S, Kurian S, Solez K, Cook D, Burke J, Rollin H . De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant. 2004; 4(11):1776-85. DOI: 10.1111/j.1600-6143.2004.00627.x. View

19.

Cosimi A, Burton R, Colvin R, Goldstein G, Delmonico F, LaQuaglia M . Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation. 1981; 32(6):535-9. DOI: 10.1097/00007890-198112000-00018. View

20.

Duzova A, Buyan N, Bakkaloglu M, Dalgic A, Soylemezoglu O, Besbas N . Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant Proc. 2003; 35(8):2878-80. DOI: 10.1016/j.transproceed.2003.10.087. View